|
Series | Year | No. of patients | Implant/allograft and site of the tumor | 5 year survival of the implant or the allograft or last follow-up | Complications/revision | Infection | Recurrence | MSTS score |
|
(1) Gupta et al. [4] | 2006 | 8 | Knee-sparing distal femoral endoprosthesis | Mean follow-up: 24 months | 0 | 1 patient developed septicemia two weeks after surgery | 0 | The mean was 80% (57% to 96.7%) |
(2) Agarwal et al. [3] | 2010 | 6 | Custom implant prosthesis | Mean follow-up: 12–27 months 1 patient died | 0 | 2 deep infection | 1 | The score ranged from 27 to 30 |
(3) Wong et al. [6] | 2013 | 8 | 6 femur, 1 tibia, and 1 proximal humerus | Mean follow-up: 41 months | 0 | 0 | 0 | The mean score was 29.1 (range, 28–30) |
(4) Spiegelberg et al. [5] | 2009 | 8 | Stanmore proximal tibia replacement epiphyseal sparing | The mean follow-up: 35 months | 1 periprosthetic fracture | 0 | 1 converted to BKA | The mean score was 24 of 30 79% (57% to 90%) |
This study | 2019 | 28 | Custom Joint-Sparing Endoprosthesis (JSE), from Stanmore | The mean follow-up: 3 years | 3 loosening 2 of them revised with new JSE | 0 | 6, 2 of them received AKA | The mean score was 90% (83–96%) |
|